Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
Want to see BCLI full AI Analyst Report?
Top Page
Brainstorm Cell Therapeutics
(OTC:BCLI)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.67
▲(16.84% Upside)
Action:Reiterated
Date:05/16/26
The score is primarily weighed down by weak financial performance (minimal revenue, ongoing losses, heavy cash burn, and negative equity implying financing/dilution risk). Technical indicators also point to subdued momentum, while valuation provides limited support due to the absence of meaningful earnings-based metrics and no dividend yield data.
Positive Factors
Proprietary autologous cell therapy platform (NurOwn)
NurOwn represents a durable, platform-oriented business model: autologous MSC-derived therapies targeting neurodegeneration can be applied across multiple indications. The patient‑derived approach reduces certain immunogenicity concerns and creates a differentiated clinical pathway and IP focus that can support long-term franchise value if clinical validation continues.
Negative Factors
Minimal revenue and lack of commercialization
The business is not generating meaningful product revenue, indicating no commercialized offering and high dependence on development-stage outcomes. Persistent negative gross profit and absence of recurring revenue mean the company cannot self-fund operations, making long-term viability contingent on successful trials or external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary autologous cell therapy platform (NurOwn)
NurOwn represents a durable, platform-oriented business model: autologous MSC-derived therapies targeting neurodegeneration can be applied across multiple indications. The patient‑derived approach reduces certain immunogenicity concerns and creates a differentiated clinical pathway and IP focus that can support long-term franchise value if clinical validation continues.
Read all positive factors
Brainstorm Cell Therapeutics (BCLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.95M
Dividend YieldN/A
Average Volume (3M)22.93K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS Growth52.48%
CountryUS
Employees27
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.94
Shares Outstanding11,034,775
10 Day Avg. Volume25,343
30 Day Avg. Volume22,935
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market Cap1.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-109.90
Enterprise Value/Ebitda-1.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Brainstorm Cell Therapeutics Business Overview & Revenue Model
Company Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy...
How the Company Makes Money
null...
Brainstorm Cell Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements towards clinical trials and strong community support, but these were overshadowed by financial challenges, NASDAQ delisting, and funding uncertainties. The sentiment is balanced between optimism for future trials and concern over current financial hurdles.Positive Updates
FDA Clearance for Phase IIIb Trial
Brainstorm Cell Therapeutics received FDA clearance to initiate a pivotal Phase IIIb trial, ENDURANCE, for NurOwn in early-stage ALS patients. This provides regulatory clarity and strengthens the trial's foundation.
Negative Updates
NASDAQ Delisting
Brainstorm's stock transitioned from NASDAQ to OTCQB due to noncompliance with NASDAQ's minimum shareholder equity requirement.
Read all updates
Q2-2025 Updates
Positive
Negative
FDA Clearance for Phase IIIb Trial
Brainstorm Cell Therapeutics received FDA clearance to initiate a pivotal Phase IIIb trial, ENDURANCE, for NurOwn in early-stage ALS patients. This provides regulatory clarity and strengthens the trial's foundation.
Read all positive updates
Company Guidance
During the Brainstorm Cell Therapeutics Second Quarter 2025 Conference Call, the company emphasized its commitment to advancing the NurOwn platform for ALS treatment through a planned Phase IIIb trial called ENDURANCE, following FDA clearance in May. The trial's design has been agreed upon with the FDA under a Special Protocol Assessment (SPA), aiming to support a future Biologics License Application (BLA). Financially, Brainstorm reported R&D expenditures of $1.1 million for the quarter ending June 30, 2025, up from $0.9 million in 2024, and a net loss of $2.9 million compared to $2.5 million the previous year. The company is actively seeking funding to initiate the trial and regain NASDAQ compliance, following a transition to the OTCQB. Additionally, a Citizens Petition has been filed with the FDA by ALS patients and families, advocating for a de novo review of NurOwn's data, which includes promising five-year survival statistics from an expanded access program.Brainstorm Cell Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -85.00K | 0.00 | -240.00K | -265.00K | -285.00K | -260.00K |
| EBITDA | -8.73M | -9.75M | -11.31M | -16.93M | -23.99M | -24.28M |
| Net Income | -9.57M | -10.31M | 11.62M | -17.19M | -24.28M | -24.46M |
Balance Sheet | ||||||
| Total Assets | 571.00K | 715.00K | 1.83M | 4.21M | 8.45M | 29.28M |
| Cash, Cash Equivalents and Short-Term Investments | 15.00K | 29.00K | 187.00K | 1.30M | 2.98M | 22.09M |
| Total Debt | 1.49M | 208.00K | 720.00K | 1.27M | 4.09M | 5.08M |
| Total Liabilities | 11.76M | 11.01M | 9.60M | 9.07M | 11.47M | 9.94M |
| Stockholders Equity | -11.01M | -10.29M | -7.76M | -4.86M | -3.02M | 19.34M |
Cash Flow | ||||||
| Free Cash Flow | -6.66M | -6.97M | -9.09M | -20.48M | -19.35M | -26.59M |
| Operating Cash Flow | -6.66M | -6.97M | -9.09M | -20.46M | -19.32M | -26.27M |
| Investing Cash Flow | 0.00 | 0.00 | 12.00K | 2.19M | 998.00K | 323.00K |
| Financing Cash Flow | 5.04M | 6.88M | 7.97M | 18.98M | 238.00K | 6.97M |
Brainstorm Cell Therapeutics Technical Analysis
Positive
0.57
Price Trends
0.80
Negative
0.70
Positive
0.68
Positive
Market Momentum
-0.02
Negative
46.74
Neutral
63.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Positive. The current price of 0.57 is below the 20-day moving average (MA) of 0.69, below the 50-day MA of 0.80, and below the 200-day MA of 0.68, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 46.74 is Neutral, neither overbought nor oversold. The STOCH value of 63.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BCLI.
Brainstorm Cell Therapeutics Risk Analysis
Brainstorm Cell Therapeutics disclosed 64 risk factors in its most recent earnings report. Brainstorm Cell Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Brainstorm Cell Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $7.95M | -1.23 | 212.08% | ― | ― | 52.48% | |
43 Neutral | $3.69M | -0.21 | 261.84% | ― | -35.62% | 70.55% | |
| ― | $58.61M | -1.38 | -165.94% | ― | -70.00% | 14.70% | |
| ― | $13.34M | -0.51 | -24.80% | ― | -4.23% | -17.96% |
* Healthcare Sector Average
BCLI
Brainstorm Cell Therapeutics
0.71
-0.40
-35.77%
AIM
AIM ImmunoTech
0.24
-8.25
-97.14%
TCRT
Alaunos Therapeutics
2.37
-0.27
-10.23%
PMCB
PharmaCyte Biotech
0.80
-0.22
-21.96%
CYCN
Cyclerion Therapeutics
3.16
-0.09
-2.77%
Brainstorm Cell Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Brainstorm Cell Therapeutics Adds Shares to Equity Incentive Plan
Neutral
Feb 27, 2026
On February 24, 2026, Brainstorm Cell Therapeutics Inc. entered into a $1 million private placement with an accredited investor, structured in up to eight closings, selling common stock and pre-funded warrants at about $0.60 per share equivalent. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.